Skip to content
ChickenStockChickenStock
Research207940
Samsung Biologics logo

Samsung Biologics (207940) stock

KOSPI · Pharmaceuticals

KRW 1,406,000-0.35%(-5,000)

As of Nov 16, 12:45 PM KST

Events and reference metrics · 1

Compares the share price with the company's earnings, net assets and sales. Check trading status and financial notes separately.

Price date for the multiples · Nov 16, 2026 · Financial period · Trailing twelve months

P/E and P/S use the latest four quarters where available · P/B uses the latest equity · Computed in-house by ChickenStock

P/E

32.75x

P/B

7.77x

P/S

14.29x

Earnings

Revenue, operating profit and net income from periodic reports filed with DART, Korea’s regulatory filing system.

Quarters and year-to-date
PeriodRevenueOperating profitNet incomeRevenue YoY
Q2 2026Consolidated · Filed Aug 14, 2026KRW 1.3 trillionKRW 586.4 billionKRW 430.7 billion—
Q1 2026Consolidated · Filed May 15, 2026KRW 1.3 trillionKRW 580.8 billionKRW 469.2 billion—
Q4 2025Consolidated · Filed May 15, 2026KRW 308.6 billionKRW 378.1 billionKRW 510 billion—
Q3 2025Consolidated · Filed Nov 14, 2025KRW 1.7 trillionKRW 728.8 billionKRW 574.5 billion+39.9%
Q2 2025Consolidated · Filed Aug 14, 2025KRW 1.3 trillionKRW 475.6 billionKRW 324.4 billion+11.5%
Q1 2025Consolidated · Filed May 15, 2025KRW 1.3 trillionKRW 486.7 billionKRW 375.6 billion+37.1%
Fiscal years
PeriodRevenueOperating profitNet incomeRevenue YoY
FY2025Consolidated · Filed May 15, 2026KRW 4.6 trillionKRW 2.1 trillionKRW 1.8 trillion—
FY2024Consolidated · Filed Aug 14, 2025KRW 4.5 trillionKRW 1.3 trillionKRW 1.1 trillion—
  • Q2 2026 is computed as H1 2026 minus Q1 2026.
  • Q4 2025 is computed as FY2025 minus 9M 2025.
  • Q3 2025 is computed as 9M 2025 minus H1 2025.
  • Q2 2025 is computed as H1 2025 minus Q1 2025.
Original filing (DART)

Short selling and securities lending

Short sales as a share of trading value, the reported short position and the securities lending balance.

Short-sale share
24.96%
Of trading value on Nov 13, 2026
Short-sale value
KRW 21.43 billion
Previous 20-day average 17.33%
Net short position
381,095 shares
As of Nov 11, 2026 · reported with a two-trading-day lag
Lending balance
1,039,239 shares
As of Nov 13, 2026 · 2.25% of listed shares
Recent short-sale days
DateShareValue
Nov 13, 202624.96%KRW 21.43 billion
Nov 12, 202650.98%KRW 84.07 billion
Nov 11, 202622.29%KRW 31.23 billion
Nov 10, 202618.01%KRW 21.32 billion
Nov 9, 202632.32%KRW 38.79 billion
Nov 6, 202611.88%KRW 22.97 billion
Nov 5, 202616.66%KRW 28.18 billion
Nov 4, 202614.72%KRW 20.43 billion
Nov 3, 202616.79%KRW 16.65 billion
Nov 2, 20269.56%KRW 6.99 billion

The short-sale share is short-sale value divided by total trading value that day. The lending balance also includes stock lent for purposes other than short selling.

Samsung Biologics (207940) stock information

KOSPI

Samsung Biologics (207940) is listed on KOSPI. Its market capitalization is about KRW 65 trillion. On trailing-twelve-month earnings the P/E ratio is 32.75, and the P/B ratio is 7.77. Return on equity is 23.7%. These figures are computed in-house from official filings and are reference information only.

Samsung Biologics — frequently asked questions

What is the P/E ratio of Samsung Biologics (207940)?
On a trailing-twelve-month basis, 207940 trades at a P/E ratio of 32.75. It is calculated as market capitalization divided by net income attributable to controlling interests, using official filings. Reference information only.
What is the market capitalization of Samsung Biologics?
207940 has a market capitalization of about KRW 65 trillion. The figure moves with the share price and is refreshed each trading day.
Is this page investment advice?
No. Every figure on this page is factual reference information compiled from public filings. It is not investment advice, not a price forecast and not a recommendation to buy or sell. Investment decisions rest with the user.

All metrics, scores, and content provided by ChickenStock are reference information derived from market data. They are not investment advice or a solicitation to trade. Investment decisions and their consequences rest with the user.